跳至主要内容
临床试验/JPRN-UMIN000012183
JPRN-UMIN000012183尚未招募未知

Efficacy and safety of simeprevir with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C - Efficacy and safety of simeprevir with pegylated interferon alfa and ribavirin

Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology0 个研究点目标入组 500 人开始时间: 2013年11月1日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional,observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Co-infection with hepatitis B virus 2) Co-infection with anti-human immunodeficiency virus 3) Other forms of liver disease (alcohol liver disease, autoimmune hepatitis etc.) 4) Decompensated cirrhosis, Liver failure 5) Severe multisystem disease, Severe immunodeficiency 6) Contraindication to pegylated interferon 7) Contraindication to ribabirin

研究者

发起方
Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology

相似试验